Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial

R.T.D. Oliver(University of Cambridge), SP Stenning(Medical Research Council), Ronald de Wit(Erasmus MC Cancer Institute), Robert E. Coleman(University of Sheffield), John D. Graham(Charles Sturt University), MD Mason(Velindre Cancer Centre), GM Mead(Southampton General Hospital), JK Joffe, GJS Rustin(Mount Vernon Hospital), Hans von der Maase(University of Copenhagen), SJ Kirk(Medical Research Council), Nina Aass(Royal Marsden Hospital)
The Lancet
July 1, 2005
10.1016/s0140-6736(05)66984-x
Cited by 447

Related Papers

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
|Journal of Clinical Oncology|2005|1.9k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k